

## Special Issue

# Innovations and Prospects in Single Cell RNA-seq for Biomedical Research

### Message from the Guest Editor

Single-cell RNA sequencing (scRNA-seq) is becoming an important tool for biomedical research, which has revolutionized our approach to addressing tissue and cellular heterogeneity and powered the study of gene expression dynamics. Recent technological advancements have significantly reduced costs, increased throughput, and facilitated the integration of multi-omic data. Analyzing scRNA-seq data requires sophisticated computational tools, which are continuously being improved. Refining methods for data analysis and presentation is crucial for better interpretation and reproducibility of scRNA-seq data, which is essential for its wide adoption in biomedical research and potential clinical applications. Research efforts integrating scRNA-seq with other omic approaches, including genomics, epigenomics, and proteomics, hold great promise for making groundbreaking discoveries. Thus, this Special Issue of *Biomedicines* invites submissions on both applied and methodological studies, focusing on the research, development, and clinical applications of scRNA-seq.

---

### Guest Editor

Dr. Hui-Qi Qu

The Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

---

### Deadline for manuscript submissions

closed (30 September 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/213049](https://mdpi.com/si/213049)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).